AR and RNA-binding in prostate cancer resistance
Official title: RNA-binding as a new paradigm for androgen receptor-mediated prostate cancer therapeutic resistance
Funded at Wayne State University · NIH-11541342 · Data updated 2026-11-12
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wayne State University NIH-funded |
| Lab location | 1 site (Detroit, United States) |
| Project start | April 1, 2025 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $535,500 |
| NIH project number | 7R01CA301628-03 |
| Project ID | NIH-11541342 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with advanced prostate cancer driven by AR signaling who may develop resistance to current AR-targeted therapies.
✕Less likely to help
Patients whose cancer does not rely on AR signaling or that do not harbor mechanisms addressed by RNA-binding pathways may see little benefit.
What this research studies
This project studies how prostate cancer that uses androgen receptor signaling continues to grow even after current AR-targeted therapies. It looks at how AR binds RNA and regulates splicing factors, which may help the cancer persist despite treatment. Using biologic models and cell lines, the researchers will map AR’s RNA targets and see how these interactions affect cancer cell growth. The goal is to identify new ideas for delaying progression and overcoming resistance in patients. Results could point to novel strategies to keep the disease in check longer.
Why it matters
Potential benefit: If successful, the work could lead to new approaches that slow or prevent resistance to AR-targeted therapies in prostate cancer.
How similar studies have gone: Early studies show AR can bind RNA and influence splicing factors, suggesting this is a plausible resistance mechanism.
Where this research is happening
-
Wayne State University
Detroit, United States Active
Researchers
- Principal investigator: Dong, Yan — Wayne State University
- Study coordinator: Dong, Yan
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
New microfluidic platform to test prostate cancer drugs using patient tumor cells
A new microfluidic, open platform uses patient-derived prostate cancer cells to create multi-culture tumor models that could better predict whether a treatment will work for Veterans.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.